Introduction
============

The Bethesda System for Reporting Thyroid Cytopathology has been widely adopted following its proposal at a State-of-the-Science Conference in 2007, and has served as the primary method of interpreting thyroid fine-needle aspiration (FNA). It provides a 6-tiered standardized system with associated implied risks of malignancy for each diagnostic category \[[@b1-usg-17053]\]. Whereas thyroid nodules assigned to the Bethesda category VI (malignant) show cytomorphologic features conclusive for malignancy and have an implied risk of malignancy of 97%-99%, thyroid nodules assigned classified as Bethesda categories III (atypia of undetermined significance or follicular lesion of undetermined significance \[AUS/FLUS\]) and V (suspicious for malignancy) show cytomorphologic features inconclusive for malignancy, with implied risks of malignancy of 5%-15% and 60%-70%, respectively \[[@b1-usg-17053]\].

In addition to its original role as a diagnostic tool, recent research has reported possible associations between Bethesda categories and pathological tumor characteristics \[[@b2-usg-17053]-[@b4-usg-17053]\]. Higher Bethesda categories at FNA have been associated with a larger pathological size, N stage, lymphovascular invasion, extrathyroidal extension, and aggressive variants of papillary thyroid carcinoma (PTC) \[[@b2-usg-17053]-[@b4-usg-17053]\]. However, the populations and methods have varied considerably across studies, including various histologic types of both thyroid malignancies and PTC and differing in whether Bethesda categories V and VI were combined \[[@b2-usg-17053]-[@b4-usg-17053]\]. Furthermore, the risks of poor pathological factors differ across histologic subtypes, and a previous study reported that there were no differences in pathologic features according to Bethesda categories when comparing PTCs of the same histologic subtype \[[@b3-usg-17053]\].

Therefore, the purpose of this study was to investigate the associations of Bethesda categories III, V, and VI with the clinical and pathological features of thyroid nodules surgically confirmed as conventional PTCs.

Materials and Methods
=====================

Study Population
----------------

Our institutional review board approved this retrospective study, and the requirement for informed consent was waived. From March 2014 to October 2015, 2,173 consecutive patients underwent preoperative ultrasonography (US) and were confirmed to have conventional PTC at our institution. Among them, 80 patients with coexisting multiple tumors of other histologic subtypes were excluded. All the remaining 2,093 patients underwent US-FNA (n=2,018) or core biopsy (n=75) prior to surgery. Among the 2,018 patients who underwent US-FNA, 1,990 had a Bethesda category III (n=98, 4.9%), V (n=730, 36.7%), or VI (n=1,162, 58.4%) lesion on preoperative US-FNA, which was performed either at our institution (n=335) or at an outside clinic (n=1,655). FNA slides that were performed at outside clinics were reviewed by the pathology department of our institution. These 1,990 patients (mean age, 44.1 years; range, 10 to 79 years) constituted our study population. Of the 1,990 patients, 1,564 were women (mean age, 43.9 years; range, 10 to 79 years) and 426 were men (mean age, 44.7 years; range, 19 to 77 years). The median pathological tumor size was 9.6 mm (range, 1 to 130 mm).

US, US-FNA, and Cytological Diagnoses
-------------------------------------

At our institution, preoperative US for staging is routinely performed on patients for whom thyroid surgery is planned. US was performed by one of 15 board-certified radiologists with 1-20 years of experience in thyroid imaging, using a 5- to 12-MHz linear probe (EPIQ5 or iU22, Philips Medical Systems, Bothell, WA, USA). The US features and US assessment of thyroid nodules were prospectively recorded at the time of preoperative US. The internal components were classified as solid, predominantly solid (\>50% solid for a mixed nodule), or predominantly cystic (\>50% cystic for a mixed nodule). Echogenicity was classified as hyperechogenicity, isoechogenicity, hypoechogenicity, or marked hypoechogenicity \[[@b5-usg-17053]\]. Margins were classified as well-circumscribed, microlobulated, or irregular. Calcifications were categorized as microcalcifications, macrocalcifications, or no calcifications. Shape was classified as taller-than-wide (greater in its anteroposterior dimension than in its transverse dimension) or wider-than-tall. The US features that were considered suspicious for malignancy included marked hypoechogenicity, microlobulated or irregular margins, microcalcifications, and a taller-than-wide shape. Thyroid nodules that showed at least one of the above suspicious US features were assessed as suspicious, and nodules without suspicious US features were assessed as probably benign.

The Bethesda classification has been used at our institution since December 2009. Bethesda category VI is assigned whenever the cytomorphologic features are conclusive for malignancy \[[@b1-usg-17053]\]. Bethesda category V is assigned if only 1-2 characteristic features of PTC are present, if they are only focal and not widespread throughout the follicular cell population, or if the sample is sparsely cellular \[[@b1-usg-17053]\]. Bethesda category III is assigned when thyroid FNAs cannot be easily classified as benign, suspicious, or malignant \[[@b1-usg-17053]\]. During the study period, the cytological diagnosis was performed by one of five pathologists with at least 4 years of experience in thyroid cytopathology, who was arbitrarily assigned according to the hospital schedule.

Surgical Procedure and Pathology
--------------------------------

Total or near-total thyroidectomy was performed in patients with multiple tumors, extrathyroidal invasion, or lymph node metastasis (LNM) upon preoperative evaluation or intraoperative findings. Central compartment neck dissection including the paratracheal, pretracheal, and prelaryngeal lymph nodes was routinely performed in all patients. Bilateral central compartment neck dissection was performed in patients who underwent total or near-total thyroidectomy and ipsilateral central compartment neck dissection was performed in patients who underwent hemithyroidectomy. Lateral compartment neck dissection was selectively performed in patients diagnosed with lateral LNM on preoperative US-FNA. If suspicious lymph nodes were found at the time of surgery, an intraoperative frozen biopsy was performed. In patients confirmed to have lateral LNM, the lateral neck compartments including levels 2, 3, 4, and anterior 5 were dissected. Of the 1,990 patients with conventional PTC, 1,073 (53.9%) underwent total or near-total thyroidectomy and 917 (46.1%) underwent hemithyroidectomy. One hundred and ninety-six patients (9.8%) underwent therapeutic lateral compartment neck dissection. We evaluated the pathological tumor size, multiplicity including both unilateral and bilateral tumor foci, and the presence of central and lateral LNM based on final surgical pathology reports. According to the eighth edition of the American Joint Committee on Cancer (AJCC) staging system \[[@b6-usg-17053]\], gross extrathyroidal extension was defined as extension involving major structures (strap muscles, subcutaneous soft tissue, larynx, trachea, esophagus, recurrent laryngeal nerve, prevertebral fascia, carotid artery, or mediastinal vessels) documented in the operative report.

Statistical Analysis
--------------------

Clinical and pathological variables and US assessments were compared among Bethesda categories III, V, and VI using the chisquare test for categorical variables and the analysis of variance test for continuous variables. Post hoc pairwise analysis was performed with the Bonferroni method for multiple comparison adjustment. To assess the associations between Bethesda categories and clinical variables, pathological variables, and US assessments, multinomial logistic regression analysis was carried out using Bethesda category VI as the reference. Variables that had a P-value of \<0.05 in the univariate multinomial logistic regression analysis were included in a multivariable multinomial logistic regression model to assess whether they had independent associations with the Bethesda categories. The statistical analysis was performed using SAS ver. 9.4 (SAS Inc., Cary, NC, USA) and SPSS ver. 23.0 (IBM Corp., Armonk, NY, USA).

Results
=======

Of the 1,990 patients with conventional PTC, 127 (6.4%) had gross extrathyroidal extension, 784 (39.4%) had central LNM, 196 (9.8%) had lateral LNM, and 644 (32.4%) had multiple tumors. Category VI PTCs had a higher proportion of nodules with suspicious US features than category III PTCs, a larger pathological tumor size, a higher proportion of nodules with gross extrathyroidal extension and central LNM than category III and category V PTCs, and a higher proportion of lateral LNM than category V PTCs ([Table 1](#t1-usg-17053){ref-type="table"}).

In the univariate multinomial logistic regression analysis, patients with category III PTCs were older than those with category VI PTCs (odds ratio \[OR\], 1.018; 95% confidence interval \[CI\], 1.001 to 1.035). Both category III PTCs and category V PTCs had a smaller pathological tumor size, less frequently had central LNM, and less frequently had gross extrathyroidal extension than category VI PTCs ([Table 2](#t2-usg-17053){ref-type="table"}). Category III PTCs less frequently showed suspicious US features (OR, 0.286; 95% CI, 0.120 to 0.679) and category V PTCs less frequently had lateral LNM (OR, 0.574; 95% CI, 0.411 to 0.801) and multiple tumors (OR, 0.812; 95% CI, 0.665 to 0.991) than category VI PTCs ([Figs. 1](#f1-usg-17053){ref-type="fig"}, [2](#f2-usg-17053){ref-type="fig"}).

In the multivariable multinomial logistic regression analysis, category III and category V PTCs had a smaller pathological tumor size (category III: OR, 0.934; 95% CI, 0.889 to 0.981; category V: OR, 0.969; 95% CI, 0.952 to 0.986) and less frequently had central LNM (category III: OR, 0.487; 95% CI, 0.287 to 0.827; category V: OR, 0.780; 95% CI, 0.633 to 0.962) than category VI PTCs ([Table 2](#t2-usg-17053){ref-type="table"}). Category III PTCs less frequently showed suspicious US features (OR, 0.296; 95% CI, 0.121 to 0.720) than category VI PTCs. Lateral LNM and gross extrathyroidal extension were not significantly associated with Bethesda categories in the multivariable analysis, although category V PTCs less frequently had gross extrathyroidal extension, with borderline significance (OR, 0.643; 95% CI, 0.406 to 1.017; P=0.059) ([Fig. 3](#f3-usg-17053){ref-type="fig"}).

Discussion
==========

We aimed to investigate the associations of Bethesda categories with the clinical and pathological features of conventional PTCs, using category VI as the reference. Compared with category VI PTCs, both category III and V PTCs had a smaller pathological tumor size and less frequently had central LNM. In addition, category III PTCs less frequently showed suspicious US features, and category V PTCs less frequently had gross extrathyroidal extension than category VI PTCs, with borderline significance (P=0.059). Our results show that the preoperative Bethesda categories provided valuable information regarding the pathological features of conventional PTC.

Malignant thyroid FNA diagnoses account for 4%-8% of all thyroid FNAs, of which the majority are PTCs \[[@b7-usg-17053]\]. Although certain characteristic nuclear alterations help define PTC, none of them are diagnostic in isolation or in a low frequency. The minimum criteria and number of altered cells necessary for an unequivocal diagnosis are uncertain, and cases that have some features of PTC but fall short of an unequivocal diagnosis are interpreted as category III or V, depending on the quality and quantity of changes and the reviewer's level of suspicion for PTC \[[@b7-usg-17053]\]. Nodule size has been reported to be an independent factor affecting paucicellular aspirates, and therefore, smaller conventional PTCs may result in aspirates with low cellularity and be classified as category III or V \[[@b8-usg-17053]\]. In addition, larger tumors have been associated with the presence of central LNM, which may partly explain the associations of Bethesda categories with central LNM in our study \[[@b9-usg-17053]-[@b11-usg-17053]\].

Previous studies have focused on investigating associations between Bethesda categories and aggressive characteristics of thyroid cancer, but have varied considerably in study design and results \[[@b2-usg-17053]-[@b4-usg-17053],[@b12-usg-17053],[@b13-usg-17053]\]. Category VI cytology results have been consistently associated with high-risk histologic subtypes of PTC, whereas follicular variants of PTC predominate in category III cancers \[[@b2-usg-17053]-[@b4-usg-17053],[@b12-usg-17053]\]. Those studies have also reported that a higher Bethesda category was associated with aggressive tumor characteristics, including a higher AJCC T and N category, lymphovascular invasion, extrathyroidal extension, and lymph node metastases. However, various histologic subtypes of PTC were included, which is reflected by the inclusion of the Bethesda category of follicular neoplasm or suspicious for a follicular neoplasm in the analyses \[[@b2-usg-17053]-[@b4-usg-17053],[@b12-usg-17053]\]. When performing subgroup analysis according to the histologic subtype, a study reported no difference in any aggressive features according to Bethesda categories \[[@b3-usg-17053]\]. Another recent study on conventional PTC reported that the Bethesda categories were predictive of extrathyroidal extension and lymph node metastasis, although it included both minimal and extensive extrathyroidal extension and did not differentiate between central and lateral LNM \[[@b13-usg-17053]\]. Our results were largely consistent with previous studies, showing that category III and category V PTCs less frequently exhibited central LNM and were smaller than category VI PTCs.

According to the revised AJCC eighth edition TNM classification and staging system, minimal extrathyroidal extension has been eliminated from the T criteria, with only gross extrathyroidal extension influencing the T category and stage groups \[[@b6-usg-17053]\]. This is primarily based on data indicating that minimal/microscopic extrathyroidal extension was not associated with survival outcomes, especially in small differentiated thyroid cancers \[[@b14-usg-17053]-[@b17-usg-17053]\]. In our study, category V PTCs less frequently exhibited gross extrathyroidal extension than category VI PTCs, although with borderline significance (P=0.059). In addition, the presence of malignant-appearing US features has been reported to be associated with recurrence or poor prognostic factors in patients with conventional PTC \[[@b18-usg-17053],[@b19-usg-17053]\]. In our study, category III PTCs less frequently showed suspicious US features than category VI PTCs. Therefore, our results suggest that Bethesda category III or V PTCs are less likely to be associated with poor prognostic factors.

There are several limitations to our study. First, this was a retrospective study conducted at a single institution. Second, we only included patients who underwent surgery at our institution, and therefore selection bias was inevitable. Third, preoperative US and US-FNA were performed by a large number of radiologists, thus causing potential interobserver variability. However, this is an inherent part of daily clinical practice and would be present at any other institution. Fourth, Bethesda category III (AUS/FLUS) is affected by various factors, including FNA technique and specimen quality, as well as intrinsic tumor characteristics.

In conclusion, the Bethesda categories may be associated with prognostic factors in conventional PTC. Conventional PTCs classified as preoperative Bethesda category III or V may less frequently exhibit central LNM and have a smaller pathological tumor size than those with malignant cytology.

No potential conflict of interest relevant to this article was reported.

![A 32-year-old woman with conventional papillary thyroid carcinoma that was initially diagnosed as Bethesda category III (atypia of undetermined significance or follicular lesion of undetermined significance) by fine-needle aspiration.\
A, B. Ultrasonography (A, transverse; B, longitudinal view) shows an isoechoic solid mass in the right thyroid gland with no suspicious ultrasonographic features (arrows). The pathologic tumor size was 16 mm, and there was no evidence of lymph node metastasis or gross extrathyroidal extension at surgery.](usg-17053f1){#f1-usg-17053}

![A 46-year-old woman with conventional papillary thyroid carcinoma that was initially diagnosed as Bethesda category V (suspicious for malignancy) by fine-needle aspiration.\
A, B. Ultrasonography (A, transverse; B, longitudinal view) shows a hypoechoic, irregular, non-parallel mass with spiculated margins in the left thyroid gland (arrows). The pathologic tumor size was 10 mm, and there was no evidence of lymph node metastasis or gross extrathyroidal extension at surgery.](usg-17053f2){#f2-usg-17053}

![A 24-year-old women with conventional papillary thyroid carcinoma that was diagnosed as Bethesda category VI (malignant) by fine-needle aspiration.\
A, B. Ultrasonography (A, transverse; B, longitudinal view) shows a hypoechoic, irregular mass with gross invasion of the strap muscle (arrows). At surgery, central lymph node metastasis was also diagnosed.](usg-17053f3){#f3-usg-17053}

###### 

Comparison of clinical and pathologic characteristics among Bethesda categories III, V, and VI in 1,990 patients with conventional papillary thyroid carcinoma

  Variable                         Bethesda classification   Overall P-value^[a)](#tfn1-usg-17053){ref-type="table-fn"}^   *Post hoc* pairwise P-values with Bonferroni correction^[b)](#tfn2-usg-17053){ref-type="table-fn"}^                                                                             
  -------------------------------- ------------------------- ------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ----------------------------------------------------- --------- --------- ---------
  Age (yr)                         46.5±12.7                 44.0±11.7                                                     43.9±12.0                                                                                             0.118                                                                     
  Sex                                                                                                                                                                                                                            0.371                                                 \>0.999   \>0.999   \>0.999
   Male                            72 (73.5)                 581 (79.6)                                                    911 (78.4)                                                                                                                                                                      
   Female                          26 (26.5)                 149 (20.4)                                                    251 (21.6)                                                                                                                                                                      
  US assessment                                                                                                                                                                                                                  0.019                                                 0.114     0.028     \>0.999
   Suspicious                      91 (92.9)                 709 (97.1)                                                    1,137 (97.8)                                                                                                                                                                    
   Probably benign                 7 (7.1)                   21 (2.9)                                                      25 (2.2)                                                                                                                                                                        
  Tumor size (mm)                  7.6±5.1                   8.6±6.1                                                       10.4±8.0                                                                                              \<0.001^[c)](#tfn3-usg-17053){ref-type="table-fn"}^                       
  Gross extrathyroidal extension                                                                                                                                                                                                 \<0.001                                               \>0.999   0.057     \<0.001
   Yes                             2 (2.0)                   28 (3.8)                                                      97 (8.3)                                                                                                                                                                        
   No                              96 (98.0)                 702 (96.2)                                                    1,065 (91.7)                                                                                                                                                                    
  Central lymph node metastasis                                                                                                                                                                                                  \<0.001                                               0.131     \<0.001   \<0.001
   Yes                             23 (23.5)                 250 (34.2)                                                    511 (44.0)                                                                                                                                                                      
   No                              75 (76.5)                 480 (65.8)                                                    651 (56.0)                                                                                                                                                                      
  Lateral lymph node metastasis                                                                                                                                                                                                  0.003                                                 \>0.999   0.664     0.004
   Yes                             7 (7.1)                   52 (7.1)                                                      137 (11.8)                                                                                                                                                                      
   No                              91 (92.9)                 678 (92.9)                                                    1,025 (88.2)                                                                                                                                                                    
  Multiplicity                                                                                                                                                                                                                   0.103                                                 \>0.999   \>0.999   0.138
   Yes                             29 (29.6)                 217 (29.7)                                                    398 (34.3)                                                                                                                                                                      
   No                              69 (70.4)                 513 (70.3)                                                    764 (65.7)                                                                                                                                                                      

Values are presented as mean±standard deviation or number (%).

US, ultrasonography; ANOVA, analysis of variance.

Calculated using the chi-square test or the Fisher exact test for categorical variables and ANOVA for continuous variables.

Calculated using the chi-square test or the Fisher exact test for categorical variables and the t test for continuous variables. The post hoc pairwise P-values with the Bonferroni correction were calculated by multiplying the pairwise raw P-values by 3, which is the number of comparisons made.

Significant differences were seen between categories III and VI and between categories V and VI, using ANOVA with Bonferroni post hoc analysis.

###### 

Univariate and multivariable multinomial logistic regression analysis of 1,990 conventional papillary thyroid carcinomas using category VI as the reference

  Variable           Univariate multinomial   Multivariable multinomial                                                                     
  ------------------ ------------------------ --------------------------- --------------- --------- --------------- ------- --------------- ---------
  Age (yr)           1.018                    0.040                       1.001           0.851     1.013           0.159   0.998           0.626
                     (1.001-1.035)                                        (0.993-1.008)             (0.995-1.031)           (0.990-1.006)   
  Sex                                         0.259                                       0.537                     0.118                   0.902
   Male              1.311                                                0.931                     1.469                   1.015           
                     (0.820-2.097)                                        (0.741-1.169)             (0.907-2.380)           (0.803-1.282)   
   Female            1 (Ref.)                                             1 (Ref.)                  1 (Ref.)                1 (Ref.)        
  US assessment                               0.005                                       0.320                     0.007                   0.312
   Suspicious        0.286                                                0.742                     0.296                   0.734           
                     (0.120-0.679)                                        (0.412-1.336)             (0.121-0.720)           (0.403-1.336)   
   Probably benign   1 (Ref.)                                             1 (Ref.)                  1 (Ref.)                1 (Ref.)        
  Tumor size (mm)    0.917                    \<0.001                     0.957           \<0.001   0.934           0.007   0.969           \<0.001
                     (0.875-0.962)                                        (0.942-0.973)             (0.889-0.981)           (0.952-0.986)   
  Gross ETE                                   0.041                                       \<0.001                   0.261                   0.059
   Yes               0.229                                                0.438                     0.432                   0.643           
                     (0.056-0.943)                                        (0.285-0.674)             (0.100-1.869)           (0.406-1.017)   
   No                1 (Ref.)                                             1 (Ref.)                  1 (Ref.)                1 (Ref.)        
  Central LNM                                 \<0.001                                     \<0.001                   0.008                   0.020
   Yes               0.391                                                0.664                     0.487                   0.780           
                     (0.241-0.632)                                        (0.548-0.804)             (0.287-0.827)           (0.633-0.962)   
   No                1 (Ref.)                                             1 (Ref.)                  1 (Ref.)                1 (Ref.)        
  Lateral LNM                                 0.170                                       0.001                     0.468                   0.456
   Yes               0.576                                                0.574                     1.383                   0.870           
                     (0.261-1.267)                                        (0.411-0.801)             (0.577-3.312)           (0.603-1.255)   
   No                1 (Ref.)                                             1 (Ref.)                  1 (Ref.)                1 (Ref.)        
  Multiplicity                                0.350                                       0.041                     0.785                   0.375
   Yes               0.807                                                0.812                     0.937                   0.911           
                     (0.514-1.266)                                        (0.665-0.991)             (0.588-1.494)           (0.741-1.120)   
   No                1 (Ref.)                                             1 (Ref.)                  1 (Ref.)                1 (Ref.)        

OR, odds ratio; CI, confidence interval; US, ultrasonography; ETE, extrathyroidal extension; LNM, lymph node metastasis; Ref., Reference.
